CD133 antigen, also known as prominin-1, is a glycoprotein that in humans is encoded by the PROM1gene. It is a member of pentaspan transmembrane glycoproteins, which specifically localize to cellular protrusions. When embedded in the cell membrane, the membrane topology of prominin-1 is such that the N-terminus extends into the extracellular space and the C-terminus resides in the intracellular compartment. The protein consists of five transmembrane segments, with the first and second segments and the third and fourth segments connected by intracellular loops while the second and third as well as fourth and fifth transmembrane segments are connected by extracellular loops. While the precise function of CD133 remains unknown, it has been proposed that it acts as an organizer of cell membrane topology.
Today CD133 is the most commonly used marker for isolation of cancer stem cell (CSC) population from different tumors, mainly from various gliomas and carcinomas. Initial studies that showed ability of CD133-positive population to efficiently propagate tumor when injected into immune-compromised mice firstly were performed on brain tumors. However, subsequent studies have indicated the difficulty in isolating pure CSC populations. CD133+melanoma cells are considered a subpopulation of CSC and play a critical role in recurrence. Moreover, CD133+ melanoma cells are immunogenic and can be used as an antimelanoma vaccination. In mice the vaccination with CD133+ melanoma cells mediated strong anti-tumor activity that resulted in the eradication of parental melanoma cells. In addition, it has also been shown that CD133+ melanoma cells preferentially express the RNA helicase DDX3X . As DDX3X also is an immunogenic protein, the same anti-melanoma vaccination strategy can be employed to give therapeutic antitumor immunity in mice.
^Corbeil D, Fargeas CA, Huttner WB (July 2001). "Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein". Biochemical and Biophysical Research Communications. 285 (4): 939–44. doi:10.1006/bbrc.2001.5271. PMID11467842.
^Sanai N, Alvarez-Buylla A, Berger MS (August 2005). "Neural stem cells and the origin of gliomas". The New England Journal of Medicine. 353 (8): 811–22. doi:10.1056/NEJMra043666. PMID16120861.
^ abSingh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (September 2003). "Identification of a cancer stem cell in human brain tumors". Cancer Research. 63 (18): 5821–8. PMID14522905.
^Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PØ (February 2008). "CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells". International Journal of Cancer. 122 (4): 761–8. doi:10.1002/ijc.23130. PMID17955491. S2CID25435240.
^Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (March 2007). "Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential". European Journal of Cancer. 43 (5): 935–46. doi:10.1016/j.ejca.2007.01.017. PMID17320377.
^Miyabayashi T, Kagamu H, Koshio J, Ichikawa K, Baba J, Watanabe S, Tanaka H, Tanaka J, Yoshizawa H, Nakata K, Narita I (November 2011). "Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor". Cancer Immunology, Immunotherapy. 60 (11): 1597–608. doi:10.1007/s00262-011-1063-x. PMID21691723. S2CID25329727.
^Koshio J, Kagamu H, Nozaki K, Saida Y, Tanaka T, Shoji S, Igarashi N, Miura S, Okajima M, Watanabe S, Yoshizawa H, Narita I (October 2013). "DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells". Cancer Immunology, Immunotherapy. 62 (10): 1619–28. doi:10.1007/s00262-013-1467-x. PMID23974721. S2CID25347678.
Na YR, Seok SH, Kim DJ, Han JH, Kim TH, Jung H, Lee BH, Park JH (2009). "Isolation and characterization of spheroid cells from human malignant melanoma cell line WM-266-4". Tumour Biology. 30 (5–6): 300–9. doi:10.1159/000261073. PMID19940551. S2CID40841423.
Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y (2009). "CD133 gene overexpression is frequently observed in early colorectal carcinoma". Hepato-Gastroenterology. 56 (93): 995–7. PMID19760928.